About Crinetics
Crinetics is a company based in San Diego (United States) founded in 2008 by Scott Struthers.. Crinetics has raised $103.5 million across 19 funding rounds from investors including NIH, HHS and Orbimed. The company has 437 employees as of December 31, 2024. Crinetics offers products and services including Paltusotine, Atumelnant, and CRN09682. Crinetics operates in a competitive market with competitors including Neurocrine, Zucara Therapeutics, MBX Biosciences, Radionetics and Siolta Therapeutics, among others.
- Headquarter San Diego, United States
- Employees 437 as on 31 Dec, 2024
- Founders Scott Struthers
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Crinetics Pharmaceuticals, Inc.
-
Annual Revenue
$1.04 M-74.11as on Dec 31, 2024
-
Net Profit
$-298.41 M-39.1as on Dec 31, 2024
-
EBITDA
$-336.07 M-51.72as on Dec 31, 2024
-
Total Equity Funding
$103.5 M (USD)
in 19 rounds
-
Latest Funding Round
$350 M (USD), Post-IPO
Mar 01, 2024
-
Investors
NIH
& 12 more
-
Employee Count
437
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Crinetics
Crinetics is a publicly listed company on the NASDAQ with ticker symbol CRNX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Crinetics
Crinetics offers a comprehensive portfolio of products and services, including Paltusotine, Atumelnant, and CRN09682. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Therapy for acromegaly and carcinoid syndrome treatment
Treatment for congenital adrenal hyperplasia
Targets neuroendocrine tumors and SST2-expressing cancers
Unlock access to complete
Unlock access to complete
Leadership Team
57 people
Software Development Team
25 people
Senior Team
14 people
Operations Team
10 people
Legal and Compliance
9 people
Product Management Team
9 people
Human Resources and Administration
6 people
Finance and Accounting
6 people
Unlock access to complete
Funding Insights of Crinetics
Crinetics has successfully raised a total of $103.5M across 19 strategic funding rounds. The most recent funding activity was a Post-IPO round of $350 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 19
- Last Round Post-IPO — $350.0M
- First Round First Round
- Investors Count 13
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2024 | Amount | Post-IPO - Crinetics | Valuation |
investors |
|
| Jul, 2021 | Amount | Post-IPO - Crinetics | Valuation |
investors |
|
| Feb, 2018 | Amount | Series B - Crinetics | Valuation | Perceptive Advisors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Crinetics
Crinetics has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include NIH, HHS and Orbimed. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare sector private equity investments are managed by the firm.
|
Founded Year | Domain | Location | |
|
Health-tech companies are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Crinetics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Crinetics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Crinetics Comparisons
Competitors of Crinetics
Crinetics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Neurocrine, Zucara Therapeutics, MBX Biosciences, Radionetics and Siolta Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| domain | founded_year | HQ Location |
Developing a long-term therapeutic approach to prevent hypoglycemia in patients with diabetes
|
|
| domain | founded_year | HQ Location |
Drugs for rare endocrine diseases are developed and advanced.
|
|
| domain | founded_year | HQ Location |
Peptide-targeted radiopharmaceuticals for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Microbiome therapeutics are provided for treating chronic inflammatory diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Crinetics
Frequently Asked Questions about Crinetics
When was Crinetics founded?
Crinetics was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Where is Crinetics located?
Crinetics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Who is the current CEO of Crinetics?
Scott Struthers is the current CEO of Crinetics. They have also founded this company.
Is Crinetics a funded company?
Crinetics is a funded company, having raised a total of $103.5M across 19 funding rounds to date. The company's 1st funding round was a Series B of $63.5M, raised on Feb 07, 2009.
How many employees does Crinetics have?
As of Dec 31, 2024, the latest employee count at Crinetics is 437.
What is the annual revenue of Crinetics?
Annual revenue of Crinetics is $1.04M as on Dec 31, 2024.
What does Crinetics do?
Developer of therapies for the treatment of endocrine-related diseases and cancers. The company focuses on the development of drugs for endocrine disorders and cancers in the areas of neuroendocrinology, reproductive medicine, and womens health. Its lead candidate is CRN04777, an oral SST5 agonist for hypoglycemia.
Who are the top competitors of Crinetics?
Crinetics's top competitors include Neurocrine, Zucara Therapeutics and MBX Biosciences.
What products or services does Crinetics offer?
Crinetics offers Paltusotine, Atumelnant, and CRN09682.
Is Crinetics publicly traded?
Yes, Crinetics is publicly traded on NASDAQ under the ticker symbol CRNX.
Who are Crinetics's investors?
Crinetics has 13 investors. Key investors include NIH, HHS, Orbimed, RA Capital, and Frazier Healthcare Partners.
What is Crinetics's ticker symbol?
The ticker symbol of Crinetics is CRNX on NASDAQ.